J Rheumatol. 1985 Feb;12(1):60-7.

One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis.

The Journal of rheumatology

P Davis, H Menard, J Thompson, M Harth, F Beaudet

PMID: 3920393

Abstract

The therapeutic benefits and toxicity profile of auranofin (AF) have been compared with that of gold sodium thiomalate (GSTM) over a one-year period in 120 patients with rheumatoid arthritis. A similar number of patients on both drugs remained in the study at one year (approximately 60%), and showed similar statistically significant improvement (p less than 0.01) in all clinical variables measured. At no time during the study was there a statistically significant difference in the clinical benefit obtained with either drug. Withdrawal from the study through lack of therapeutic benefit was twice as frequent with AF as with GSTM (11 compared to 6). Withdrawal due to a toxic reaction was twice as frequent and were potentially more serious with GSTM than with AF (15 compared to 9). We conclude that AF has a therapeutic potential similar to that of GSTM, however side effects were less prevalent and, when they did cause withdrawal of the drug, were potentially less serious.

Substances

• Gold Sodium Thiomalate
• Aurothioglucose
• Auranofin
• Gold

MeSH terms

• Arthritis, Rheumatoid / drug therapy
• Arthritis, Rheumatoid / physiopathology
• Auranofin
• Aurothioglucose / adverse effects
• Aurothioglucose / analogs & derivatives
• Aurothioglucose / therapeutic use
• Blood Sedimentation
• Clinical Trials as Topic
• Female
• Gold / analogs & derivatives
• Gold Sodium Thiomalate / adverse effects
• Gold Sodium Thiomalate / therapeutic use
• Humans
• Male
• Middle Aged
• Serologic Tests

Publication Types

• Comparative Study
• Journal Article
• Research Support, Non-U.S. Gov't

LinkOut - more resources

• Medical
  • Genetic Alliance
  • MedlinePlus Health Information
• Research Materials
  • NCI CPTC Antibody Characterization Program